Authors: TAVET F LAMOURI A HEYMANS F DIVE G TOUBOUL E BLAVET N GODFROID JJ

Citation: F. Tavet et al., DESIGN AND MODELING OF NEW PLATELET-ACTIVATING-FACTOR ANTAGONISTS .2.SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 1,4-BIS-(3',4',5'-TRIMETHOXYBENZOYL)-2-ALKYL AND 2-ALKYLOXYMETHYLPIPERAZINES, Journal of lipid mediators and cell signalling, 15(2), 1997, pp. 145-159

Authors: LETEXIER L FAVRE E REDEUILH C BLAVET N BELLAHSENE T DIVE G PIROTZKY E GODFROID JJ

Citation: L. Letexier et al., STRUCTURE-ACTIVITY-RELATIONSHIPS IN PLATELET-ACTIVATING-FACTOR (PAF) .7. TETRAHYDROFURAN DERIVATIVES AS DUAL PAF ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS - SYNTHESIS AND PAF-ANTAGONISTIC ACTIVITY, Journal of lipid mediators and cell signalling, 13(3), 1996, pp. 189-205

Authors: LETEXIER L FAVRE E RONZANI N MASSICOT F BLAVET N PIROTZKY E GODFROID JJ

Citation: L. Letexier et al., STRUCTURE-ACTIVITY-RELATIONSHIPS IN PLATELET-ACTIVATING-FACTOR (PAF) .8. TETRAHYDROFURAN DERIVATIVES AS DUAL PAF ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS - ANTIACETYLCHOLINESTERASE ACTIVITY AND COMPARATIVE SAR, Journal of lipid mediators and cell signalling, 13(3), 1996, pp. 207-222

Authors: SPINNEWYN B BLAVET N PIROTZKY E BRAQUET P

Citation: B. Spinnewyn et al., PLATELET-ACTIVATING-FACTOR ANTAGONIST, BN-50730, PROTECTS AGAINST THEDEVELOPMENT OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, Journal of lipid mediators and cell signalling, 10(1-2), 1994, pp. 135-137

Authors: LAMOURI A HEYMANS F TAVET F DIVE G BATT JP BLAVET N BRAQUET P GODFROID JJ

Citation: A. Lamouri et al., DESIGN AND MODELING OF NEW PLATELET-ACTIVATING-FACTOR ANTAGONISTS .1.SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 4-BIS(3',4',5'-TRIMETHOXYBENZOYL)-2-[[(SUBSTITUTED CARBONYL AND CARBAMOYL)OXY]METHYL]PIPERAZINES, Journal of medicinal chemistry, 36(8), 1993, pp. 990-1000